This is a preview of subscription content, log in via an institution to check access.
Notes
The researchers were affiliated with Genentech, USA and Switzerland.
Reference
Morlock R, et al. A cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BV. 2013 Gastrointestinal Cancers Symposium : abstr. 417, 24 Jan 2013. Available from: URL: http://gicasym.asco.org/content/105717-133
Rights and permissions
About this article
Cite this article
Bevacizumab preferred option in mCRC. PharmacoEcon Outcomes News 671, 5 (2013). https://doi.org/10.1007/s40274-013-0130-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0130-2